S-1: CERo Therapeutics Seeks Up to $20 Million in New Offering Amidst Nasdaq Compliance Challenges

CERo Therapeutics Holdings, Inc. is launching a public offering of common stock and warrants to raise capital while facing potential delisting from the Nasdaq.

Summary

• CERo Therapeutics is offering up to a specified number of shares of common stock, along with common warrants and pre-funded warrants, to raise capital.
• The offering is structured to allow certain investors to purchase pre-funded warrants instead of common stock to avoid exceeding ownership limits.
• The company's common stock is currently listed on the Nasdaq under the symbol CERO, with a recent trading price of $0.06 per share.
• The offering will terminate on a specified date in 2024, but may be terminated earlier at the company's discretion.
• As of December 16, 2024, there were 333,580,498 shares of common stock outstanding on a fully-diluted basis.
• If all shares offered are issued, they would represent approximately a specified percentage of the company's fully-diluted shares.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced public company reporting requirements.
• The company has engaged JonesTrading Institutional Services LLC as its exclusive placement agent for the offering.
• There is no minimum offering amount required as a condition to closing this offering, and the company may sell fewer than all of the securities offered.
• The company intends to use the net proceeds from this offering, together with its existing cash, to advance its clinical programs, for working capital and other general corporate purposes.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has promising technology and has cleared its IND, it faces significant financial challenges, including a going concern warning, and is struggling to maintain its Nasdaq listing. The need for a capital raise and the potential for dilution further dampen the sentiment.

Positives

• The company has a novel cellular immunotherapy platform designed to redirect patient-derived T cells to eliminate tumors.
• The company's lead molecule, CER-1236, is believed to be efficacious in both hematological malignancies and solid tumors.
• The company has submitted an IND for CER-1236, which has been cleared by the FDA.
• The company has an agreement with a CDMO for the manufacture of CER-1236.

Negatives

• The company has incurred significant losses since its inception and expects to continue to incur losses.
• The company's independent registered public accountants have expressed substantial doubt about its ability to continue as a going concern.
• The company is highly dependent on the success of its lead product candidate, CER-1236.
• The company faces significant competition from other companies developing cancer therapies.
• The company has received notices from Nasdaq regarding non-compliance with listing requirements, including minimum bid price and market value of publicly held shares.
• The company may not be able to regain or maintain compliance with Nasdaq listing standards.

Risks

• The shares of Common Stock being offered in this prospectus represent a substantial percentage of the outstanding shares of Common Stock, and the sales of such shares, or the perception that these sales could occur, could cause the market price of the Common Stock to decline significantly.
• Sales of a substantial number of our securities in the public market by our existing securityholders could cause the price of our Common Stock and Warrants to fall.
• Certain existing securityholders purchased our securities at a price below the current trading price of such securities, and may experience a positive rate of return based on the current trading price. Future investors in us may not experience a similar rate of return.
• The company has incurred significant losses in every year since its inception and may never achieve or maintain profitability.
• The company's independent registered public accountants have expressed substantial doubt as to its ability to continue as a going concern.
• The company's business is highly dependent on the success of its lead product candidate, CER-1236.
• The company's engineered CER-T cells represent a novel approach to cancer treatment that creates significant challenges.
• The company's preclinical programs may experience delays or may never advance to clinical trials.
• Success in preclinical studies or clinical trials may not be indicative of results in future clinical trials.
• Manufacturing genetically engineered products is complex and the company may encounter difficulties in production.
• Genetic engineering of T cells to create CER-T cells is a relatively new technology.
• The company will depend on enrollment of patients in its clinical trials.
• The company faces competition from companies that have developed or may develop product candidates for the treatment of the diseases that the company may target.
• The company is highly dependent on its key personnel.
• The company will need substantial additional financing to develop its products and implement its operating plans.
• The company maintains single supply relationships for certain key components.
• Regulatory requirements in the United States and abroad governing cell therapy products have changed frequently and may continue to change in the future.
• The company's intellectual property rights are valuable, and any inability to protect them could reduce the value of its products, services and brand.
• An active trading market for the company's Common Stock may not be available on a consistent basis to provide stockholders with adequate liquidity.
• The price of the company's Common Stock may be extremely volatile, and stockholders could lose all or part of their investment.
• The company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of its securities.
• The issuance of shares of the company's Common Stock upon conversion or exercise of its outstanding Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C Warrants and other securities that the company may issue in future financing transactions may result in substantial dilution to its stockholders.
• There is no public market for Offered Common Warrants or the Pre-Funded Warrants to purchase shares of the company's common stock being offered by the company in this offering.

Future Outlook

The company intends to use the net proceeds from this offering, together with its existing cash, to advance its clinical programs, for working capital and other general corporate purposes. The company continues to believe that it will be able to initiate the planned clinical trial by early 2025.

Management Comments

• The Board of Directors expects to determine the ratio and implement the reverse stock split prior to the Nasdaq hearing.

Industry Context

The document highlights the competitive landscape of the biotechnology and pharmaceutical industries, particularly in the development of cell and gene therapies. The company faces competition from larger, better-funded companies, as well as smaller, early-stage companies. The document also notes the increasing market for CAR-T cell therapies, which is expected to exceed $10 billion globally by 2030.

Comparison to Industry Standards

• The document compares CERo's approach to traditional CAR-T cell therapies, highlighting the limitations of current CAR-T therapies in treating solid tumors and the potential of CERo's CER-T cells to overcome these limitations.
• The document also mentions that approved autologous T cell therapies and those under development by other companies have shown frequent rates of CRS, neurotoxicity, serious infections, prolonged cytopenia and hypogammaglobulinemia, and adverse events have resulted in the death of patients, which may be similar to the adverse events that may occur for CERo's T cell product candidates.

Stakeholder Impact

• Shareholders may experience dilution due to the offering and potential future issuances of Common Stock.
• Shareholders may experience a decline in the market price of the Common Stock due to the offering and potential future sales of Common Stock.
• Shareholders may lose all or part of their investment due to the volatility of the Common Stock and the company's financial challenges.
• Employees may be affected by the company's financial challenges and potential restructuring.
• Customers may be affected by the company's ability to develop and commercialize its product candidates.

Next Steps

• The company intends to initiate the planned clinical trial by early 2025.
• The company intends to submit a plan to Nasdaq to regain compliance with listing requirements.
• The company intends to determine the ratio and implement the reverse stock split prior to the Nasdaq hearing.

Key Dates

Keywords

CERo Therapeutics, Common Stock, Warrants, Pre-Funded Warrants, Cancer Therapy, Immunotherapy, Cell Therapy, Nasdaq, Clinical Trials, Biotechnology